News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of Aldafermin Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study Status:

Study closed

Contact Information:

(956) 362-8047

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objectives are to evaluate the efficacy, safety, and tolerability of aldafermin based on liver histology at 24 weeks versus placebo

Information: 

Principal Investigator
Jose Luis Almeda, MD
Co-PI
Guillermo Duran
Sponsor
NGM Biopharmaceuticals, Inc.
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram